Journal of Clinical Oncology
Articles in this Issue
Results from a phase 1/2 study of 7MW3711: A novel B7-H3 antibody-drug conjugate (ADC) incorporating a topoisomerase I inhibitor in patients with advanced solid tumors.
3035 Background: 7MW3711 is a B7-H3 targeting ADC comprised of a recombinant humanized monoclonal anti-human B7-H3 antibody conjugated to the topoisomeras...
Overall survival in hematopoietic stem cell transplant patients with hematologic malignancies: Accounting for the unobserved risk factors.
e18553 Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapy for hematologic malignancies; it is al...
A phase II basket trial evaluating the efficacy of tasurgratinib (E7090) in patients with advanced solid tumors with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE study.
3147 Background: Tasurgratinib is an orally available selective inhibitor of FGFR1-3 tyrosine kinase and is approved in Japan for biliary tract cancer wit...
Associations of age, frailty status, and comorbidity status with post-operative outcomes following CRS-HIPEC.
e16060 Background: Cytoreductive surgery, combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), is a promising intervention used to treat d...
Real-world adoption of adjuvant molecularly targeted therapy and immunotherapy for resected stage Ib-III non-small cell lung cancer within the Veterans Health Administration.
e20020 Background: Emerging evidence supports the use of adjuvant systemic therapies for appropriately selected patients with early-stage, resected non-sm...
Immune checkpoint inhibitor (ICI) efficacy in triple-negative breast cancer (TNBC) patients with liver metastases (LM): A meta-analysis.
e13131 Background: TNBC is an aggressive breast cancer (BC) subtype, and the only subtype where ICIs are approved. Approximately 50% of patients (pts) dev...
A phase 1 study of abemaciclib and niraparib as neoadjuvant therapy in hormone receptor positive and HER2 negative breast cancer.
e12598 Background: Less than 20% of hormone receptor-positive HER2-negative breast cancer (HRBC) patients (pts) achieve pathologic complete response with...
Predictive gene signature for the efficacy of pazopanib in solitary fibrous tumor: A Spanish Group for Research in Sarcoma (GEIS) study.
11540 Background: Pazopanib was shown to be active in advanced Solitary Fibrous Tumor (SFT), with 58% and 51% of the typical and malignant/ dedifferentiat...
FAITH trial: Feasibility and safety of anlotinib plus benmelstobart in patients with previously immunotherapy treated intermediate-to-advanced hepatocellular carcinoma—Amulticenter, single arm, prospective phase Ⅱ trial.
e16225 Background: In recent years, immune checkpoint inhibitors (ICIs) combined with targeted therapies have become the preferred first-line standard tre...
Doxorubicin-based chemotherapy vs gemcitabine/docetaxel in uterine leiomyosarcoma (ULMS).
11564 Background: ULMS is an aggressive uterine smooth muscle cancer. Surgery is standard for localized/advanced ULMS, and the use of adjuvant chemotherap...
Impact of relative dose intensity (RDI) of perioperative FLOT in resectable and locally advanced gastric and gastroesophageal junction adenocarcinoma.
e24089 Background: Perioperative FLOT is the standard of care for resectable locally advanced gastric (GC) and gastro-oesophageal junction (GEJ) adenocarc...
Phase I dose-escalation study of the safety and pharmacokinetics of PAS-004, a macrocyclic MEK inhibitor, for the treatment of patients with MAPK pathway–driven advanced solid tumors.
3125 Background: PAS-004 is a small molecule allosteric inhibitor of MEK 1/2 and the first macrocyclic structure MEK inhibitor in clinical development. Ma...
Association of post-surgical MRD status with neoadjuvant ctDNA dynamics, genomic mutations, and clinical outcomes in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial.
8009 Background: In AEGEAN, perioperative durvalumab (D) + neoadj CT significantly improved the primary endpoints of event...
Optimizing treatment sequencing in hepatocellular carcinoma: Impact of radioembolization timing and immune checkpoint inhibitors on survival outcomes.
e16275 Background: The optimal sequencing of available locoregional therapies and systemic treatments for patients with hepatocellular carcinoma (HCC) rem...
Harnessing EHR for goals of care: The role of electronic alerts for care optimization in gynecologic cancer patients at risk of death in 6 months.
5571 Background: This study employed the validated Surprise Question to evaluate the ability of an electronic health record (EHR) alert to predict 6-month...
The predictive role of TRAIL gene expression in immune checkpoint inhibitor (ICI)-treated patients (pts).
2637 Background: Despite FDA-approved molecular biomarkers such as PD-L1 levels, tumor mutation burden (TMB), and microsatellite instability (MSI) status,...
Combination casdatifan plus cabozantinib expansion cohort of phase 1 ARC-20 study in previously treated patients with clear cell renal cell carcinoma.
4506 Background: Hypoxia-inducible factor 2-alpha (HIF-2α) is highly dysregulated in clear cell renal cell carcinoma (ccRCC), resulting in increased expre...
INSIHGT revived: Unified 3D tissue profiling for spatially resolved, multi-marker, quantitative expression scoring at single-cell resolution for fresh and archival samples.
e15098 Background: Biology is three-dimensional, yet we lack the technology to picture the structural and molecular details throughout the tumour tissue v...
Predicting survival in malignant meningiomas: A machine learning approach.
2087 Background: Intracerebral meningiomas account for over 90% of all meningioma cases, with only 1–3% classified as malignant. Malignant meningiomas rem...
Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): Secondary results from the EA1181/CompassHER2 pCR trial.
501 Background: EA1181 (NCT04266249) is a single-arm trial of neoadjuvant THP for patients with clinical anatomic stage II...
IMMUNONET: A multicenter, open-label, proof-of-concept phase II trial evaluating NP137 as add-on therapy in advanced/metastatic solid tumors treated with standard immunotherapies.
TPS3177 Background: PD-1/PD-L1 blockade has transformed oncology by offering durable responses in various cancers. However, many patients develop resistan...
Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) or NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded analyses from CheckMate 8HW.
3501 Background: In the phase 3 CheckMate 8HW study (NCT04008030), both dual primary endpoints of progression-free survival (PFS) for first-line (1L) NIVO...
Burden and trend of breast cancer attributable to high red meat consumption in the United States from 1990-2021: An insight from the Global Burden of Disease study 2021.
10560 Background: Breast Cancer (BC) 4th most common cause of cancer in the United States (USA). In the USA, dietary factors, particularly high red meat c...
IND.241: A Canadian Cancer Trials Group liquid-biopsy informed platform trial to evaluate treatment in CDK4/6-inhibitor resistant ER+/HER2- metastatic breast.
TPS1121 Background: The combination of a CDK4/6 inhibitor + endocrine therapy (CDK4/6i+ET) is standard first-line systemic treatment for patients with ER+...
Global burden and trend of tracheal, bronchus, and lung cancer attributable to residential radon in Southeast Asia, East Asia and Oceania: A global benchmarking analysis.
e22518 Background: The burden of tracheal, bronchus and lung cancer (TBLc) attributable to residential radon (RR) in Southeast Asia (SEA), East Asia (EA),...